PL374363A1 - Sposoby identyfikowania antygenów polipeptydowych, związanych z chorobami powiązanymi z zaburzoną proliferacją komórek, i kompozycje do leczenia takich chorób - Google Patents

Sposoby identyfikowania antygenów polipeptydowych, związanych z chorobami powiązanymi z zaburzoną proliferacją komórek, i kompozycje do leczenia takich chorób

Info

Publication number
PL374363A1
PL374363A1 PL02374363A PL37436302A PL374363A1 PL 374363 A1 PL374363 A1 PL 374363A1 PL 02374363 A PL02374363 A PL 02374363A PL 37436302 A PL37436302 A PL 37436302A PL 374363 A1 PL374363 A1 PL 374363A1
Authority
PL
Poland
Prior art keywords
diseases
methods
compositions
antibodies
mitotic
Prior art date
Application number
PL02374363A
Other languages
English (en)
Inventor
Arthur D. Levinson
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL374363A1 publication Critical patent/PL374363A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL02374363A 2001-09-05 2002-09-04 Sposoby identyfikowania antygenów polipeptydowych, związanych z chorobami powiązanymi z zaburzoną proliferacją komórek, i kompozycje do leczenia takich chorób PL374363A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31750401P 2001-09-05 2001-09-05

Publications (1)

Publication Number Publication Date
PL374363A1 true PL374363A1 (pl) 2005-10-17

Family

ID=23233944

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02374363A PL374363A1 (pl) 2001-09-05 2002-09-04 Sposoby identyfikowania antygenów polipeptydowych, związanych z chorobami powiązanymi z zaburzoną proliferacją komórek, i kompozycje do leczenia takich chorób

Country Status (17)

Country Link
EP (1) EP1432446B1 (pl)
JP (2) JP5224632B2 (pl)
KR (3) KR20100061863A (pl)
CN (2) CN1578673A (pl)
AT (1) ATE506965T1 (pl)
AU (1) AU2002332838B2 (pl)
BR (1) BR0212641A (pl)
CA (1) CA2457541C (pl)
DE (1) DE60239881D1 (pl)
DK (1) DK1432446T3 (pl)
HU (1) HUP0500617A3 (pl)
IL (2) IL160659A0 (pl)
MX (1) MXPA04002084A (pl)
NZ (1) NZ531515A (pl)
PL (1) PL374363A1 (pl)
WO (1) WO2003020909A2 (pl)
ZA (1) ZA200401751B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101145506B1 (ko) * 2003-05-20 2012-05-15 이뮤노젠 아이엔씨 새로운 메이탠시노이드를 포함하는 개선된 세포독성체
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NO347360B1 (no) * 2003-10-10 2023-09-25 Immunogen Inc Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse.
HUE029925T2 (en) * 2008-04-02 2017-04-28 Macrogenics Inc HER2 / neu-specific antibodies and methods using them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
BR0015224A (pt) * 1999-10-29 2002-07-09 Genentech Inc Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
CA2397416A1 (en) * 2000-01-26 2001-08-02 Jonathan Cohen A system for developing assays for personalized medicine

Also Published As

Publication number Publication date
NZ531515A (en) 2007-11-30
IL160659A0 (en) 2004-08-31
BR0212641A (pt) 2005-04-12
KR20090104925A (ko) 2009-10-06
HUP0500617A2 (hu) 2005-10-28
WO2003020909A3 (en) 2003-11-20
EP1432446A4 (en) 2004-09-08
MXPA04002084A (es) 2004-06-07
CN1578673A (zh) 2005-02-09
JP5224632B2 (ja) 2013-07-03
EP1432446B1 (en) 2011-04-27
HUP0500617A3 (en) 2012-05-02
EP1432446A2 (en) 2004-06-30
CN101446590A (zh) 2009-06-03
ATE506965T1 (de) 2011-05-15
KR20040044850A (ko) 2004-05-31
ZA200401751B (en) 2005-07-27
KR20100061863A (ko) 2010-06-09
DE60239881D1 (de) 2011-06-09
AU2002332838B2 (en) 2007-08-02
JP2005517155A (ja) 2005-06-09
CA2457541A1 (en) 2003-03-13
DK1432446T3 (da) 2011-07-18
WO2003020909A2 (en) 2003-03-13
JP2010280691A (ja) 2010-12-16
CA2457541C (en) 2013-01-08
IL160659A (en) 2011-07-31

Similar Documents

Publication Publication Date Title
WO2020236817A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
AU3057297A (en) Targeted combination immunotherapy of cancer
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
WO2008091620A3 (en) Combination therapy comprising romidepsin and i.a. bortezomib
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
SI1663242T1 (sl) 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
WO2003049527A3 (en) Mitotic kinesin inhibitors
AU2020380603A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
EA200500300A1 (ru) Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение
WO2023201234A3 (en) Anti-variable muc1* antibodies and uses thereof
WO2004089294A3 (en) Compositions, methods and kits relating to her-2 cleavage
WO2021217130A3 (en) Chimeric antigen receptors targeting cd19 and use thereof
WO2024077023A3 (en) Cereblon-recruiting bcl-xl/bcl-2 dual degraders
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
MX2025002127A (es) Anticuerpos anti-monometil auristatina y fragmentos de anticuerpos
IL160659A0 (en) Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
MX2025014033A (es) Anticuerpos y sus conjugados de anticuerpo y farmaco
BR0116123A (pt) Carbazóis antitumorais
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
BRPI0508497A (pt) moduladores de canais de ìons e composição que os contém

Legal Events

Date Code Title Description
VOID Decisions declaring the decisions on the grant of the patent lapsed